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1  | INTRODUC TION
In a 2016 US Food and Drug Administration public meeting on patient‐
focused drug development, transplant recipients voiced their desire 
to have immunosuppressive therapy individualized and simplified to 
avoid side effects while ensuring efficacy.1 Unfortunately, when in‐
duction therapy is selected for renal transplant recipients, current 
evidence shows that an individual’s clinical risk factors only account 
for 10%‐33% of the observed variation in practice, while transplant 
center effect was responsible for the majority (51%‐61%) of the 
 
Received: 29 August 2018  |  Revised: 11 October 2018  |  Accepted: 4 November 2018
DOI: 10.1111/ajt.15177
O R I G I N A L  A R T I C L E
HLA‐DR/DQ molecular mismatch: A prognostic biomarker for 
primary alloimmunity
Chris Wiebe1,2 | Vasilis Kosmoliaptsis3,4,5 | Denise Pochinco2 | Ian W. Gibson2,6 |  
Julie Ho1,7 | Patricia E. Birk8 | Aviva Goldberg8 | Martin Karpinski1 | Jamie Shaw1 |  
David N. Rush1 | Peter W. Nickerson1,2,7
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in 
any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
© 2018 The Authors American Journal of Transplantation published by Wiley Periodicals, Inc. on behalf of The American Society of Transplantation and the 
American Society of Transplant Surgeons
Abbreviations: ABMR, antibody‐mediated rejection; dnDSA, de novo donor‐specific antibody; PRA, panel reactive antibody; TCMR, T cell–mediated rejection.
1Department of Medicine, University of 
Manitoba, Winnipeg, Manitoba, Canada
2Shared Health Services Manitoba, 
Winnipeg, Manitoba, Canada
3Department of Surgery, University of 
Cambridge, Addenbrooke's Hospital, 
Cambridge, UK
4NIHR Blood and Transplant Research Unit 
in Organ Donation and Transplantation at 
the University of Cambridge, Cambridge, UK
5The NIHR Cambridge Biomedical Research 
Centre, Cambridge, UK
6Department of Pathology, University of 
Manitoba, Winnipeg, Manitoba, Canada
7Department of Immunology, University of 
Manitoba, Winnipeg, Manitoba, Canada
8Department of Pediatrics and Child 
Health, University of Manitoba, Winnipeg, 
Manitoba, Canada
Correspondence
Chris Wiebe
Email: cwiebe@hsc.mb.ca
Funding information
Canadian Institutes of Health Research; 
National Institute for Health Research; 
Research Manitoba; Evelyn Trust
Alloimmune risk stratification in renal transplantation has lacked the necessary prog‐
nostic biomarkers to personalize recipient care or optimize clinical trials. HLA mo‐
lecular mismatch improves precision compared to traditional antigen mismatch but 
has not been studied in detail at the individual molecule level. This study evaluated 
664 renal transplant recipients and correlated HLA-DR/DQ single molecule eplet 
mismatch with serologic, histologic, and clinical outcomes. Compared to traditional 
HLA-DR/DQ whole antigen mismatch, HLA-DR/DQ single molecule eplet mismatch 
improved the correlation with de novo donor‐specific antibody development (area 
under the curve 0.54 vs 0.84) and allowed recipients to be stratified into low, inter‐
mediate, and high alloimmune risk categories. These risk categories were significantly 
correlated with primary alloimmune events including Banff ≥1A T cell–mediated re‐
jection (P = .0006), HLA-DR/DQ de novo donor-specific antibody development 
(P < .0001), antibody‐mediated rejection (P < .0001), as well as all‐cause graft loss 
(P = .0012) and each of these correlations persisted in multivariate models. Thus, 
HLA-DR/DQ single molecule eplet mismatch may represent a precise, reproducible, 
and widely available prognostic biomarker that can be applied to tailor immunosup‐
pression or design clinical trials based on individual patient risk.
K E Y W O R D S
clinical research/practice, clinical trial design, histocompatibility, kidney transplantation/
nephrology, major histocompatibility complex (MHC), rejection: antibody‐mediated (ABMR), 
rejection: T cell mediated (TCMR), risk assessment/risk stratification
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variation.2 Compounding the problem, randomized controlled trials 
(RCTs) of immunosuppression minimization that have attempted to 
identify “low risk” recipients using clinical, serologic, and histologic 
criteria have been unsuccessful, suggesting that traditional risk fac‐
tors hold little utility to personalize patient care.3‐5 Thus, an unmet 
need in transplantation is the accurate definition of an individual’s 
alloimmune risk for a given donor at the time of transplant: a fun‐
damental requirement if the field is to move to precision medicine.
In 2017, the American Society of Transplantation and the 
American Society of Histocompatibility and Immunogenetics es‐
tablished the Sensitization in Transplantation: Assessment of Risk 
(STAR) Working Group. The goal of this expert panel is to conduct 
critical reviews of the pretransplant diagnostics literature and 
make recommendations for alloimmune risk assessment building 
on the 2009 Kidney Disease: Improving Global Outcomes (KDIGO) 
and the 2013 Transplant Society clinical practice guidelines.6‐8 
The STAR 2017 report created a framework that recommended 
2 independent risk assessments: 1 related to the risk of immuno‐
logic memory and a second related to the risk of a primary (ie, 
de novo) alloimmune response posttransplant. In this context, the 
STAR Working Group identified that the HLA molecular mismatch 
was a key determinant of an individual’s primary alloimmune risk 
and called for research to determine optimal approaches to define 
HLA molecular mismatch risk categories.
In this study, building on our prior work using HLAMatchmaker 
as a computational tool to assess donor-recipient HLA related‐
ness,9,10 we evaluated a novel approach to quantify HLA molecu‐
lar mismatch allowing us to more precisely classify individuals into 
low, intermediate, or high alloimmune risk categories at the time 
of kidney transplant. These risk categories correlated with primary 
alloimmune events (ie, T cell–mediated rejection [TCMR], de novo 
donor‐specific antibody [dnDSA] development, antibody‐mediated 
rejection [ABMR]), as well as all‐cause graft loss.
2  | CONCISE METHODS
2.1 | Study population
Approval was obtained from the institutional review board 
(H2011:211) and was in adherence with the declaration of Helsinki. 
Seven hundred twenty‐four adult and pediatric consecutive renal 
transplants between January 1999 and July 2016 were considered 
for inclusion. Patients with primary nonfunction (n = 17), or pre‐
transplant donor-specific antibody (DSA) (n = 43) were excluded, 
leaving 664 recipients (adult n = 606, pediatric n = 58) for analy‐
sis. Median follow‐up was 91 months (range 18‐226). Recipients 
who moved (n = 33) or died with a functioning graft (n = 112) were 
censored at last follow‐up. Standard immunosuppression consisted 
of a calcineurin inhibitor (tacrolimus [87%] or cyclosporin [13%]), 
mycophenolate mofetil, and prednisone. Induction therapy with 
thymoglobulin (21%) or basiliximab (18%) was used in 39% of pa‐
tients. Details on clinical, serologic, and histologic monitoring post‐
transplant have been reported previously and can be found in the 
Supplemental Methods.9,11
2.2 | HLA typing and epitope mismatch 
identification
High-resolution Class II HLA typing (HLA-DRβ1/3/4/5 and HLA-
DQα1/β1) was performed using sequence‐specific oligonucleotide 
probes or sequence-specific primer technology (LABType® HD 
SSO, Micro SSP™; One Lambda, Los Angeles, CA). HLAMatchmaker 
F I G U R E  1   HLA donor-recipient mismatch drives allorecognition. An amino acid polymorphism (yellow) present in the donor and not 
present in the recipient is the most basic unit of mismatch. An eplet is defined as a single polymorphic amino acid or a small patch of 
polymorphic amino acids within a 3 angstrom (0.3 nm) radius on or near the surface of an HLA molecule. An eplet represents the smallest 
functional unit of an epitope‐paratope interface, which may drive antibody specificity through interactions with the central complementary 
determining regions of the antibody paratope. The complete epitope (green) represents all amino acids within a 15 angstrom (1.5 nm) radius 
typical for an antibody paratope
Polymorphic
amino acid
Eplet
3  radius 
Epitope
15  radius
1710  |     WIEBE Et al.
software (HLA DRDQDP Matching version 2.0) was used to define 
Class II eplet mismatches between donors and recipients.
HLA eplet identification is based on 2 underlying principles: (a) the 
immune system recognizes and develops antibodies against nonself‐
antigens, or more specifically the epitopes on those antigens, while ig‐
noring self-antigens/epitopes; and (b) epitope binding affinity is largely 
determined by a small number of polymorphic amino acids near the cen‐
ter of the epitope.12 An eplet is defined as a single polymorphic amino 
acid or a small patch of polymorphic amino acids within a 3 angstrom 
(0.3 nm) radius (Figure 1) on or near the surface of an HLA molecule. An 
eplet represents the smallest functional unit of an epitope‐paratope in‐
terface, which may drive antibody specificity through interactions with 
the central complementary‐determining regions of the antibody para‐
tope. An epitope is defined by the complete antigen‐antibody interface 
(≈15 angstrom [1.5 nm]) made up of amino acids essential for specificity 
as well as those that affect affinity but not specificity.
2.3 | Traditional HLA mismatch vs molecular HLA 
mismatch assessment
Class II HLA-DR/DQ donor-recipient mismatch was evaluated by 
3 different methods in this study (Figure 2). First is the traditional 
whole antigen method where each HLA-DRβ1 or HLA-DQβ1 donor 
antigen is assigned 1 mismatch if different from either recipient 
antigen, resulting in a sum score of 0, 1, or 2 at each locus. The sec‐
ond method, published previously,9 uses HLAMatchmaker DRDQDP 
(version 2) to determine the eplet mismatches for each of the HLA-
DRβ1/3/4/5, HLA-DQα1, and HLA-DQβ1 alleles, which are summed for 
each locus. In both of the first 2 methods the total score for that HLA 
locus is correlated with dnDSA development at that locus. The third 
method used HLAMatchmaker to determine the eplet mismatch for 
each HLA-DR or HLA-DQ molecule individually and correlated the 
single molecule eplet mismatch with dnDSA development against 
that molecule specifically (Table 1). Thresholds were then developed 
by receiver operating characteristic (ROC) curve analysis (see sec‐
tion 2.1) so that recipients could be categorized by whether any of 
their individual HLA-DR or DQ molecules had eplet mismatch loads 
above or below the thresholds. For HLA-DR each maternal and 
parenteral HLA-DRβ1 (n = 1328), HLA-DRβ3 (n = 481), HLA-DRβ4 
(n = 392), HLA-DRβ5 (n = 231) donor alleles were considered. Donor 
null alleles at HLA-DRβ3/4/5 (n = 224) did not count toward the total. 
For HLA-DQ, α and β alleles inherited as a haplotype were consid‐
ered as 1 HLA-DQα1β1 molecule (n = 1328).
2.4 | Statistics
Comparisons between baseline predictors and clinical outcomes 
were done using Student t test for parametric continuous variables 
F I G U R E  2   Comparing HLA mismatch methods to define low risk for dnDSA. Methods of quantifying HLA mismatches are compared 
using a theoretical example at the HLA-DQ locus. dnDSA, de novo donor-specific antibody
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and Wilcoxon‐rank test for nonparametric data. Chi‐squared or 
Fisher exact tests were used to test categorical variables. 
Comparisons across multiple groups were done using Kruskal‐Wallis 
test for nonparametric data and analysis of variance for parametric 
variables. Survival analysis was done by the Kaplan‐Meier method 
using the log-rank test for significance. ROC analysis was used to 
identify HLA-DR or DQ molecule specific thresholds best associ‐
ated with dnDSA development. Cox proportional hazards model was 
used to evaluate predictors of Banff ≥1A TCMR-free survival, dnDSA 
free‐survival, ABMR‐free survival, and all‐cause graft loss. Variables 
for multivariate regression were selected based on bivariate screen‐
ing, with P values ≤.2 used to identify candidates for inclusion in the 
final model. Statistical software used was JMP (version 14.0; SAS 
Inc., Cary, NC).
3  | RESULTS
This consecutive cohort (n = 664) had a median follow-up of 91 months 
(range 18‐227 months) and a median 10‐year all‐cause graft survival of 
74% (death-censored graft survival of 87%). Screening serial sera, HLA 
dnDSA developed in 82 recipients (12%) at an average of 5.9 (range 
0.5‐17.0) years posttransplant. De novo DSA developed against Class I 
alone (n = 10), Class II alone (n = 50), or Class I and II (n = 22). Two recipi‐
ents with Class I dnDSA alone went on to graft loss at a median 11 years 
(range 9‐13 years) after dnDSA development. Graft survival in the Class I 
dnDSA alone group was not different from the no dnDSA group (P = .39, 
Figure S1). Recipients who developed Class II dnDSA alone, or Class I 
and II dnDSA had decreased graft survival compared with those who 
did not develop dnDSA (P < .0001).
3.1 | Defining low risk for primary alloimmunity by 
HLA molecular mismatch
The range of HLA-DRβ1/3/4/5 single molecule eplet mismatches was 
0-22 and the range of HLA-DQα1β1 single molecule eplet mismatches 
was 0-31. Each HLA-DRβ1/3/4/5 and HLA-DQα1β1 molecule was an‐
alyzed individually for the risk of dnDSA development against that 
molecule. Using this approach, a ROC analysis identified a molecule 
specific threshold of ≥7 HLA-DR eplet mismatches and ≥9 HLA-DQ 
eplet mismatches associated with an area under the curve (AUC) of 
0.84 and 0.84 for HLA-DR and HLA-DQ dnDSA development, re‐
spectively (sensitivity, 81% and 90%, specificity 75% and 64%, re‐
spectively, Table 1, Figure S2). By comparison using the traditional 
HLA whole antigen mismatch as a correlate with dnDSA development, 
the AUC was only 0.54 and 0.58 for HLA-DR, and DQ, respectively.
Using the HLA-DR/DQ molecule-specific mismatch thresholds, 
recipients were stratified into 3 groups: Group A (n = 93) HLA-
DR = 0 and HLA-DQ = 0; Group B (n = 73) HLA-DR = 1-6 and/or 
HLA-DQ = 1-8; and Group C (n = 498) HLA-DR ≥7 or HLA-DQ ≥9. 
Baseline demographics within these groups are compared in Table 2. 
Recipients in Group B were more likely to have a repeat transplant 
(P < .01), younger age (P = .03), and were less likely to have received T
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induction therapy (P < .01) compared to Group C. Of note, risk fac‐
tors known to influence dnDSA development such as nonadherence, 
maintenance immunosuppression, and tacrolimus coefficient of vari‐
ation were similar among the 3 groups.
3.2 | Comparison of HLA‐DR/DQ mismatch 
quantification methods
Traditional HLA-DR/DQ whole antigen mismatch, HLA-DR/DQ 
eplet mismatch sum thresholds (previously published HLA-DR and 
DQ thresholds each ≤11),9 and HLA-DR/DQ single molecule eplet 
mismatch thresholds were compared as correlates for HLA-DR/DQ 
dnDSA‐free survival (Figure 3) and Banff ≥1A TCMR-free survival 
(Figure 4). Table 1 and Figures 1 and 2 outline the key differences 
between these 3 methods.
Traditional HLA-DR/DQ whole antigen mismatch greater than 
zero was associated with significantly lower HLA-DR/DQ dnD‐
SA‐free survival (P = .0003). However, there was no statistical dif‐
ference in HLA-DR/DQ dnDSA‐free survival between HLA-DR/
DQ whole antigen risk groups other than zero (P = .48, Figure 3A). 
This was also true in a locus-specific analysis of HLA-DR or HLA-
DQ dnDSA development (Figure S3). HLA-DR/DQ eplet mismatch 
sum also was associated with HLA-DR/DQ dnDSA‐free survival 
(Figure 3B). Using the previously published thresholds of 11 HLA-DR 
or DQ eplet mismatches to risk stratify recipients, a significant dose-
response relationship was demonstrated (P < .0001, Figure 3B).9 
By comparison, HLA-DR/DQ single molecule eplet mismatch risk 
groups with HLA-DR <7 and HLA-DQ <9 mismatches (Groups A 
and B, n = 166, 25% of the cohort) developed HLA-DR/DQ dnDSA 
in only 2 recipients (1.2%) in the first 10 years posttransplant. 
However, recipients with single molecule HLA-DR ≥7 or HLA-DQ ≥9 
eplet mismatches (Group C, n = 498) had significantly increased risk 
of HLA-DR/DQ dnDSA development (P < .0001, Figure 3C).
At least 1 surveillance or for‐cause biopsy was performed in the 
first-year posttransplant in 522/664 (79%) of patients. Traditional 
HLA-DR/DQ whole antigen mismatch greater than zero was asso‐
ciated with significantly decreased Banff ≥1A TCMR-free survival 
in the first year posttransplant (P = .0085, Figure 4A). However, 
there was no difference in Banff ≥1A TCMR-free survival between 
HLA-DR/DQ whole antigen risk groups other than zero (P = .49, 
Figure 4A). HLA-DR/DQ eplet mismatch sum was also associated 
with Banff ≥1A TCMR-free survival (P = .0013, Figure 4B). Using 
the thresholds of ≥11 HLA-DR or DQ eplet mismatches, a trend of 
increased risk of Banff ≥1A TCMR across eplet mismatch groups 
was evident (Figure 4B). Using HLA-DR/DQ single molecule eplet 
mismatch risk groups, recipients with HLA-DR <7 and HLA-DQ 
<9 (Groups A and B, n = 166, 25% of the cohort) developed Banff 
≥1A TCMR in ≤10% of recipients in the first year posttransplant. 
However, recipients with HLA-DR ≥7 or HLA-DQ ≥9 single mol‐
ecule eplet mismatches (Group C, n = 498) had significantly in‐
creased risk of Banff ≥1A TCMR (20% at 12 months, P = .0018, 
Figure 4C).
3.3 | Defining intermediate and high risk for primary 
alloimmunity by HLA molecular mismatch
Groups A and B were combined into a single Low Risk category 
based on the prior analysis (HLA-DR <7 and HLA-DQ <9). Because 
TA B L E  2   HLA-DR/DQ single molecule eplet mismatch subgroup demographics
Group A Group B Group C
P value P valueDR=0 and DQ=0 DR=1‐6 and/or DQ=1‐8 DR≥7 or DQ≥9
n = 93 n = 73 n = 498 All groups Group B vs C
First transplant 93% 89% 97% .0118 .0075
Recipient age (y) 40.4 ± 14.1 41.0 ± 15.0 44.9 ± 16.5 .0028 .0269
Donor age (y) 38.7 ± 12.8 40.9 ± 16.0 40.6 ± 15.0 .4386 .7205
Living donor 77% 45% 44% <.0001 .8183
Ethnicity (white vs other) 79% 62% 65% .0186 .6172
Cold ischemic time (h) 4.2 ± 3.6 6.9 ± 5.6 7.3 ± 5.5 <.0001 .7962
Delayed graft function 7% 19% 14% .0333 .2845
Induction therapy 20% 27% 44% <.0001 .0056
Basiliximab 14% 15% 20%
Thymoglobulin 7% 12% 24%
Tacrolimus vs cyclosporin 90% 88% 87% .6485 .8627
Tacrolimus CV 0‐12 mo 
(n = 582)
34.2 ± 9.4 39.1 ± 13.9 36.3 ± 12.1 .1728 .1459
Mycophenolate 100% 100% 100% ns ns
Nonadherence 14% 12% 16% .6458 .3987
CV, coefficient of variation; ns, not significant.
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F I G U R E  3   Comparing HLA mismatch 
methods to define low risk for dnDSA. 
Traditional HLA-DR/DQ whole antigen 
mismatch (A), HLA-DQ/DQ eplet 
mismatch sum (B), and HLA-DR/DQ 
single molecule eplet mismatch (C) are 
correlated with de novo donor‐specific 
antibody‐free survival
0.4
0.5
0.6
0.7
0.8
0.9
1.0
0 1 2 3 4 5 6 7 8 9 10
0.4
0.5
0.6
0.7
0.8
0.9
1.0
0 1 2 3 4 5 6 7 8 9 10
0.4
0.5
0.6
0.7
0.8
0.9
1.0
0 1 2 3 4 5 6 7 8 9 10
Follow-up (years)
p=0.0003
p<0.0001
p<0.0001
H
LA
-D
R
/D
Q
 d
nD
S
A
 F
re
e 
S
ur
vi
va
l
H
LA
-D
R
/D
Q
 d
nD
S
A
 F
re
e 
S
ur
vi
va
l
H
LA
-D
R
/D
Q
 d
nD
S
A
 F
re
e 
S
ur
vi
va
l
DR + DQ Antigen Mismatch 0 
DR + DQ Antigen Mismatch 1-2 
DR + DQ Antigen Mismatch 3-4
DR Mismatch 0 and DQ Mismatch 0  
DR Mismatch 1-10 and/or DQ Mismatch 1-10  
DR Mismatch >11 or DQ Mismatch >11
HLA-DR/DQ Eplet Mismatch Sum
(n=93) 
(n=114) 
(n=457)
(n=91) 
(n=287) 
(n=286)
HLA-DR/DQ Whole Antigen Mismatch
DR Mismatch 0 and DQ Mismatch 0  
1 DR Mismatch 1-6 and/or DQ Mismatch 1-8 
1 DR Mismatch 7 or 1 DQ Mismatch 9
HLA-DR/DQ Single Molecule Eplet Mismatch
(n=93) 
(n=73) 
(n=498)
A
B
C
p=0.0131
p=0.0046
1714  |     WIEBE Et al.
F I G U R E  4   Comparing HLA mismatch 
methods to define low risk for TCMR. 
Traditional HLA-DR/DQ whole antigen 
mismatch (A), HLA-DQ/DQ eplet 
mismatch sum (B), and HLA-DR/DQ 
single molecule eplet mismatch (C) are 
correlated with Banff ≥1A T cell–mediated 
rejection‐free survival. TCMR, T cell–
mediated rejection
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Group C recipients represented 75% of the cohort, we sought to 
stratify these recipients further by repeating the ROC analysis at the 
HLA-DR and DQ loci after exclusion of recipients in the Low Risk 
category. For HLA-DR, no additional cutoff could be identified; how‐
ever, a single molecule threshold of ≥15 HLA-DQ eplet mismatches 
was identified. When Group C recipients were split into groups of 
above or below 15 HLA-DQ eplets, 2 alloimmune risk categories 
were identified: Intermediate Risk (HLA-DR ≥7 and HLA-DQ ≤14, 
or HLA-DR 0-6 and HLA-DQ 9-14), and High Risk (HLA-DR 0-22 
and HLA-DQ 15-31). Recipient demographics of the low, intermedi‐
ate, and high HLA molecular mismatch risk categories are shown in 
Table S1. Differences between groups were found for primary trans‐
plant, recipient age, living donor, cold ischemic time, and induction 
therapy. There were no significant differences in baseline demo‐
graphic between intermediate‐ and high‐risk groups.
Low, Intermediate, and High HLA molecular mismatch risk 
categories were significantly associated with Banff ≥1A TCMR 
(P = .0006, Figure 5A). In a Cox model, Banff ≥1A TCMR-free sur‐
vival was significantly less for recipients in the Intermediate (hazard 
ratio [HR] 2.02, 95% confidence interval [CI] 1.1‐3.9, P = .0230) and 
High (HR 3.33, 95% CI 1.9‐6.3, P < .0001) risk categories compared 
to the Low Risk category. Correlates associated with Banff ≥1A 
TCMR are shown in Table S2. Significant multivariate correlates of 
Banff ≥1A TCMR-free survival were recipient age (HR 0.98, 95% CI 
0.97‐0.99, P = .0037), cyclosporin vs tacrolimus (HR 5.39, 95% CI 
3.6‐8.0, P < .0001), delayed graft function (HR 2.04, 95% CI 1.3-3.1, 
P = .0035), and HLA molecular mismatch risk category (HR High vs 
Low 3.94, 95% CI 2.2-7.5, P < .0001; HR High vs Intermediate 1.6, 
95% CI 1.1-2.4, P = .0233; HR Intermediate vs Low 2.28, 95% CI 
1.2-4.5, P = .0075).
Low, Intermediate, and High HLA molecular mismatch risk cat‐
egories were significantly associated with dnDSA development 
(P < .0001, Figure 5B). In a Cox model, dnDSA‐free survival was sig‐
nificantly less for recipients in the Intermediate (HR 10.18, 95% CI 
3.0‐63.5, P < .0001), and High (HR 20.8, 95% CI 6.4-127.4, P < .0001) 
risk categories compared to the Low Risk category. Correlates asso‐
ciated with dnDSA‐free survival are shown in Table S3. Significant 
multivariate correlates of dnDSA development were recipient age 
(HR 0.97, 95% CI 0.96‐0.99, P = .0010), cyclosporin vs tacrolimus 
(HR 2.11, 95% CI 1.3-3.4, P = .0043), nonadherence (HR 2.83, 95% 
CI 1.7-4.6, P < .0001), and HLA molecular mismatch risk category 
(HR High vs Low 18.31, 95% CI 5.6-11.4, P < .0001; HR High vs 
Intermediate 1.84, 95% CI 1.1-3.1, P = .0149; HR Intermediate vs 
Low 9.96, 95% CI 2.9-62.1, P < .0001).
At least 1 renal biopsy was available in 57/72 (79%) of recipi‐
ents post-dnDSA. ABMR developed in 40/57 (70%) of recipients 
post‐dnDSA development. ABMR‐free survival was significantly 
associated with HLA molecular mismatch risk categories (P < .0001, 
Figure 5C). Correlates associated with ABMR‐free survival are shown 
in Table S4. Significant multivariate correlates of ABMR were recip‐
ient age (HR 0.98, 95% CI 0.96‐0.99, P = .0116), nonadherence (HR 
3.52, 95% CI 2.0‐6.3, P < .0001), and HLA molecular mismatch risk 
category (HR High vs Low 5.06, 95% CI 2.1-14.9, P < .0001; HR High 
vs Intermediate 1.87, 95% CI 1.0‐3.6, P = .0420; HR Intermediate vs 
Low 2.71, 95% CI 1.0-8.3, P = .0394).
3.4 | HLA molecular mismatch correlates with all‐
cause graft loss
Low, Intermediate, and High HLA molecular mismatch risk catego‐
ries were significantly associated with all‐cause graft loss (P = .0003, 
Figure S4). Correlates associated with all-cause graft loss are shown 
in Table S5. In a multivariate analysis, covariates significantly as‐
sociated with all‐cause graft loss were recipient age (HR 1.03, 95% 
CI 1.01-1.04, P < .0001), delayed graft function (HR 2.56, 95% CI 
1.80‐3.58, P < .0001), nonadherence (HR 2.00, 95% CI 1.35‐2.87, 
P = .0006), and alloimmune risk category (HR High vs Low 1.66, 
95% CI 1.12‐2.53, P = .0120; HR High vs Intermediate 1.20, 95% CI 
0.9‐1.7, P = .3; HR Intermediate vs Low 1.39, 95% CI 0.9-1.2, P = .1).
4  | DISCUSSION
The key finding in this study is that in the absence of donor‐spe‐
cific memory (ie, no preformed DSA by solid phase single antigen 
bead assessment), quantifying the differences of HLA-DR/DQ mis‐
matches at the molecular level can improve precision in primary al‐
loimmune risk categorization. As a prognostic biomarker available 
pretransplant, its potential application includes the development of 
personalized immunosuppression protocols, as well as being a drug 
development tool for enrichment/stratification in clinical trial design 
to improve trial efficiency. These applications would address major 
unmet needs in transplantation from both the perspective of the pa‐
tient and the pharmaceutical industry/academia.13,14
Traditional alloimmune risk factors reported by KDIGO and re‐
cently enumerated in the 2017 Consensus on Managing Modifiable 
Risk in Transplantation report were pretransplant DSA, panel reac‐
tive antibody (PRA) >0%, younger recipient age, African American 
ethnicity, and HLA-DR mismatch.7,15 Pretransplant DSA, a measure 
of alloimmune memory, correlates with ABMR, transplant glomeru‐
lopathy, and graft loss.16 However, as pretransplant DSA is avoided 
in most kidney transplants, methods for primary alloimmune risk 
stratification are needed. Although elevated PRA has been cor‐
related with allograft outcomes, recent work using state‐of‐the‐art 
antibody assessment in combination with more complete HLA typ‐
ing (ie, HLA-C, HLA-DQ, and HLA-DP) has shown that when pre‐
formed DSA are ruled out, calculated PRA alone is not prognostic of 
graft outcomes.17‐19 Younger recipient age is a well‐known correlate 
of alloimmune risk in transplantation, likely as a result of a more ro‐
bust immune system, even after adjustment for the higher preva‐
lence of nonadherence.10 Unfortunately, there is a lack of studies 
to define what age cutoff may be important, and how recipient age 
might be used in the precision medicine context. Although certain 
ethnic minorities have been associated with worse outcomes, these 
data are confounded by socioeconomic status, HLA mismatch, and 
differences in drug metabolism.20 Moreover, population migration 
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and genetic admixture makes self‐reported ethnicity increasingly 
imprecise such that ethnicity may be prognostic at a population level 
but is unlikely to have any prognostic utility at an individual level.21,22
Since the 1950s, HLA mismatch has been known to correlate 
with transplant outcome.23 Unfortunately, while traditional HLA 
whole antigen mismatch, especially Class II, correlates with out‐
comes at the population level, the lack of precision limits its utility 
at the individual level. Traditional HLA whole antigen mismatches 
only evaluates whether the donor and recipient molecules are the 
same or different. The issue is that some mismatched HLA molecules 
are nearly identical while others may be very disparate—information 
ignored with traditional HLA mismatch assessment. Fortunately, this 
relative difference can be captured and quantified by HLA molec‐
ular mismatch comparisons24,25 such as the HLAMatchmaker eplet 
mismatch analysis used in this study. Because the range of eplet mis‐
matches is wide, it is logical to ask what cutoff might best correlate 
with a primary alloimmune response. De novo DSA development is a 
useful outcome for model development because it can be detected 
noninvasively, its onset can be determined by serial screening, and 
specificity can be assigned to the single molecule mismatch level. 
Previously, it was reported that the sum of adding the eplet mis‐
matches within the same locus correlated with dnDSA development 
at that locus.9 However, since single molecule specificity of dnDSA 
can be determined in most cases, the analysis can be refined further 
to ask if the eplet mismatch for each individual molecule correlates 
with the development of dnDSA to that molecule.26 The single mol‐
ecule approach would be expected to be more precise, especially for 
patients who have only 1 of the 2 molecules mismatched.
Using the traditional HLA whole antigen mismatch as a correlate 
with dnDSA development, the AUC was only 0.54 and 0.58 for HLA-
DR and DQ, respectively. When applying the sum of the eplet mis‐
match within a locus, the AUC improved to 0.72 for both HLA-DR 
and DQ.9 This was enhanced further in the current study using the 
single molecule eplet analysis to an AUC of 0.84 for HLA-DR and 
DQ. Notably, results of the single molecule method provide multiple 
individual scores within each locus for each recipient. Thus, to bring 
this evaluation to the individual recipient level, thresholds were de‐
termined and used to categorize each recipient as low, intermediate, 
or high primary alloimmune risk based on the molecular mismatch 
scores across all HLA-DRβ1/3/4/5 and HLA-DQα1/β1 molecules. These 
risk categories were highly correlated with dnDSA development, 
ABMR, Banff ≥1A TCMR, and all-cause graft loss.
The need for reliable prognostic and predictive biomarkers at 
the time of transplant to allow individualization of immunosup‐
pression in patients without alloimmune memory has been recog‐
nized.1 A prognostic biomarker is one that indicates an increased 
(or decreased) likelihood of a future clinical event.27 HLA-DR/DQ 
molecular mismatch has consistently been shown to correlate with 
a significantly increased risk of dnDSA development, ABMR, trans‐
plant glomerulopathy, and graft loss after adjustment for other risk 
factors.9‐11,26,28,29 A predictive biomarker is used to identify indi‐
viduals who are more likely to respond after exposure to a partic‐
ular medical product or environmental agent.27 In this regard, Class 
II HLA eplet mismatch has been shown in 2 observational cohort 
studies and 1 RCT to identify high alloimmune risk patients who 
have increased rates of dnDSA development, rejection, and graft 
loss when immunosuppression is minimized through protocol‐driven 
withdrawal or recipient nonadherence.3,9,28 Conversely, and of equal 
importance, these studies also identified a subset of recipients with 
low alloimmune risk who tolerated immunosuppression minimi‐
zation. If validated in prospective clinical trials, this would provide 
the evidence that HLA-DR/DQ single molecule mismatch can act as 
both a prognostic and a predictive biomarker capable of identifying 
which individuals require more or less immunosuppression to con‐
trol their primary alloimmune response.21
As a prognostic biomarker, HLA-DR/DQ molecular mismatch has 
several favorable characteristics. It is available at the time of trans‐
plant, modern HLA typing methods already provide the inputs nec‐
essary for its evaluation, and analysis software is free and is already 
being incorporated into HLA typing software from vendors. Thus, 
HLA-DR/DQ molecular mismatch is cost effective, reproducible, 
and will be widely available in histocompatibility laboratories.
At present, given excellent short‐term clinical outcomes, the eval‐
uation of novel drugs focuses on the average treatment effect in the 
overall kidney transplant population requiring Phase 3 clinical trials 
lasting ≥5 years with relatively large sample sizes to demonstrate su‐
periority to standard of care.13‐15,30 This inefficient trial design is in 
part due to the lack of robust and precise pretransplant risk assess‐
ment for primarily alloimmune events resulting in the inclusion of het‐
erogeneous populations. Using the HLA-DR/DQ molecular mismatch 
score as a prognostic biomarker could significantly address this issue 
by enriching Phase 2 and 3 clinical trials with patients based upon risk 
categorization in studies evaluating novel drugs.
4.1 | Limitations
Due to the relatively small sample size and the associated risk of type 
II error, risk quantification should be interpreted with caution, and 
should be validated in an independent cohort. Histology was avail‐
able in 79% of recipients in the first year posttransplant; however, 
97% of the death‐censored graft loss occurred in the cohort with at 
least 1 biopsy. Methods of risk stratification will need to be tested 
prospectively and in independent cohorts with varying ethnicities to 
confirm their general applicability.
5  | CONCLUSIONS
A prerequisite to precision medicine is a prognostic biomarker that 
correlates with clinical outcomes, is reproducible, and ideally is 
widely available and cost effective. Using thresholds identified for 
dnDSA development as an outcome, we show that the HLA-DR/DQ 
molecular mismatch score allows for low‐, intermediate‐, and high‐
risk stratification for Banff ≥1A TCMR, dnDSA development, ABMR, 
and all‐cause graft loss. Given that all transplant programs world‐
wide are supported by accredited histocompatibility laboratories, 
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this biomarker could be readily applied at little additional cost. Once 
validated, the HLA-DR/DQ molecular mismatch score could be used 
to tailor immunosuppression based on individual patient risk, as well 
as in the design of clinical trials.
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